Opinion - Chemoprevention of breast cancer with selective oestrogen-receptor modulators

被引：166

作者：

Jordan, V. Craig ^{[1
]}

机构：

[1] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA

来源：

NATURE REVIEWS CANCER | 2007年 / 7卷 / 01期

关键词：

D O I：

10.1038/nrc2048

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Twenty years ago, a new therapeutic dimension was conceived that not only had the potential to treat and prevent osteoporosis, but to prevent breast and endometrial cancer at the same time. As osteoporosis was known to be caused by oestrogen withdrawal after menopause, whereas breast and endometrial cancer are caused by unopposed oestrogen action, the new tissue-selective oestrogens and anti-oestrogens, or selective oestrogen-receptor modulators (SERMs), had to recruit new networks to activate or suppress target tissues selectively. New medicines now promise to provide chemoprevention strategies for women at risk for the development of many diseases.

引用

收藏

页码：46 / 53

页数：8

相关论文

共 100 条

[81] Coactivation of liver receptor homologue-1 by peroxisome proliferator-activated receptor γ coactivator-1α on aromatase promoter II and its inhibition by activated retinoid X receptor suggest a novel target for breast-specific antiestrogen therapy [J].

Safi, R ;

Kovacic, A ;

Gaillard, S ;

Murata, Y ;

Simpson, ER ;

McDonnell, DP ;

Clyne, CD .

CANCER RESEARCH, 2005, 65 (24) :11762-11770

[82] Declining estrogen receptor-β expression defines malignant progression of human breast neoplasia [J].

Shaaban, AM ;

O'Neill, PA ;

Davies, MPA ;

Sibson, R ;

West, CR ;

Smith, PH ;

Foster, CS .

AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2003, 27 (12) :1502-1512

[83] Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription [J].

Shang, YF ;

Hu, X ;

DiRenzo, J ;

Lazar, MA ;

Brown, M .

CELL, 2000, 103 (06) :843-852

[84] The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen [J].

Shiau, AK ;

Barstad, D ;

Loria, PM ;

Cheng, L ;

Kushner, PJ ;

Agard, DA ;

Greene, GL .

CELL, 1998, 95 (07) :927-937

[85] Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer [J].

Shou, J ;

Massarweh, S ;

Osborne, CK ;

Wakeling, AE ;

Ali, S ;

Weiss, H ;

Schiff, R .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (12) :926-935

[86] TISSUE-SPECIFIC PROMOTERS REGULATE AROMATASE CYTOCHROME-P450 EXPRESSION [J].

SIMPSON, ER ;

MAHENDROO, MS ;

MEANS, GD ;

KILGORE, MW ;

CORBIN, CJ ;

MENDELSON, CR .

JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1993, 44 (4-6) :321-330

[87] Aromatase - A brief overview [J].

Simpson, ER ;

Clyne, C ;

Rubin, G ;

Boon, WC ;

Robertson, K ;

Britt, K ;

Speed, C ;

Jones, M .

ANNUAL REVIEW OF PHYSIOLOGY, 2002, 64 :93-127

[88] Coregulator function: A key to understanding tissue specificity of selective receptor modulators [J].

Smith, CL ;

O'Malley, BW .

ENDOCRINE REVIEWS, 2004, 25 (01) :45-71

[89] Raloxifene hydrochloride [J].

Snyder, KR ;

Sparano, N ;

Malinowski, JM .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (18) :1669-1675

[90] Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine [J].

Stearns, V ;

Johnson, MD ;

Rae, JM ;

Morocho, A ;

Novielli, A ;

Bhargava, P ;

Hayes, DF ;

Desta, Z ;

Flockhart, DA .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (23) :1758-1764

← 1 2 3 4 5 6 7 8 9 10 →